Pingyang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pingyang Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Congqing Lu
Ultrasonography Department, the First People's Hospital of Lianyungang (Lianyungang Clinical Medical College of Nanjing Medical University), Lianyungang 222000, China
1 shared publicationHonge Li
Ultrasonography Department, the First People's Hospital of Lianyungang (Lianyungang Clinical Medical College of Nanjing Medical University), Lianyungang 222000, China
1 shared publicationKun Liu
UCardiology Department, the First People's Hospital of Lianyungang (Lianyungang Clinical Medical College of Nanjing Medical University), Lianyungang 222000, China
1 shared publication- Ming Yu
Department of Medical Ultrasound, The First People’s Hospital of Lianyungang, Lianyungang, Jiangsu, China
1 shared publication Yan Wang
Ultrasonography Department, the First People's Hospital of Lianyungang (Lianyungang Clinical Medical College of Nanjing Medical University), Lianyungang 222000, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2020
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 9 (3) , 1187-1197
3D-STI evaluation of the effect of dexrazoxane on the mechanical properties of right ventricular myocardium in breast cancer patients treated with pirarubicin
Background: Observation indexes used to evaluate the effect of dexrazoxane–anthracycline combinations in breast cancer often only take into account the clinical symptoms, or left ventricular ejection fraction (LVEF), biomarkers [such as creatine kinase MB (CK-MB), brain natriuretic peptide (BNP) and cardiac troponin T (cTnT)], or tumor recurrence rate, improvement of autonomic nerve function or economic benefits. This study aimed to evaluate the effect of dexrazoxane on the changes of mechanical properties of right ventricular myocardium in patients who underwent pirarubicin chemotherapy with three-dimensional speckle-tracking imaging (3D-STI). Methods: A total of 64 breast cancer post-operation patients who received pirarubicin chemotherapy were randomly divided into two groups: the experimental group (with dexrazoxane added) and the control group (without dexrazoxane). The mechanical properties of the right ventricular myocardium were monitored by 3D-STI before and after chemotherapy. The levels of serum hypersensitive troponin I (hs-cTnI) and N-terminal B-type pro-natriuretic peptide (NT-proBNP) as well as conventional echocardiographic parameters were also measured. Results: After chemotherapy, right ventricular global longitudinal strain (RVGLS) and right ventricular global area strain (RVGAS) were significantly reduced in both groups (PConclusions: Dexrazoxane can alleviate the toxicity of pirarubicin in the right ventricular myocardium. 3D-STI is a potential new method for early and accurate evaluation of the mechanical properties and functional changes of the right ventricular myocardium.
- 1 May 2020
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 9 (3) , 1187-1197
Open Access3D-STI evaluation of the effect of dexrazoxane on the mechanical properties of right ventricular myocardium in breast cancer patients treated with pirarubicin
Background: Observation indexes used to evaluate the effect of dexrazoxane–anthracycline combinations in breast cancer often only take into account the clinical symptoms, or left ventricular ejection fraction (LVEF), biomarkers [such as creatine kinase MB (CK-MB), brain natriuretic peptide (BNP) and cardiac troponin T (cTnT)], or tumor recurrence rate, improvement of autonomic nerve function or economic benefits. This study aimed to evaluate the effect of dexrazoxane on the changes of mechanical properties of right ventricular myocardium in patients who underwent pirarubicin chemotherapy with three-dimensional speckle-tracking imaging (3D-STI). Methods: A total of 64 breast cancer post-operation patients who received pirarubicin chemotherapy were randomly divided into two groups: the experimental group (with dexrazoxane added) and the control group (without dexrazoxane). The mechanical properties of the right ventricular myocardium were monitored by 3D-STI before and after chemotherapy. The levels of serum hypersensitive troponin I (hs-cTnI) and N-terminal B-type pro-natriuretic peptide (NT-proBNP) as well as conventional echocardiographic parameters were also measured. Results: After chemotherapy, right ventricular global longitudinal strain (RVGLS) and right ventricular global area strain (RVGAS) were significantly reduced in both groups (PConclusions: Dexrazoxane can alleviate the toxicity of pirarubicin in the right ventricular myocardium. 3D-STI is a potential new method for early and accurate evaluation of the mechanical properties and functional changes of the right ventricular myocardium.